ZBH Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.1B
-5.2%
2.2B
+4.3%
2.1B
-7.0%
2.2B
+12.1%
2.0B
Cost of Revenue
760.5M
+19.7%
635.5M
+10.3%
576.2M
-27.3%
792.4M
+7.7%
735.8M
Gross Profit
1.3B
-15.5%
1.5B
+2.1%
1.5B
+4.1%
1.5B
+14.7%
1.3B
Operating Expenses
994.9M
-18.1%
1.2B
+6.9%
1.1B
-12.3%
1.3B
+41.8%
914.3M
R&D
105.9M
+1.0%
104.8M
+1.4%
103.4M
-12.9%
118.7M
+2.4%
115.9M
SG&A
855.0M
-4.9%
899.3M
+5.8%
849.9M
-2.6%
872.3M
+7.5%
811.4M
Operating Income
307.5M
-5.7%
326.1M
-12.6%
373.2M
+141.6%
154.5M
-56.0%
351.3M
EBITDA
603.9M
-3.6%
626.7M
-3.5%
649.5M
+19.2%
544.8M
-17.0%
656.3M
Net Income
192.9M
-3.4%
199.6M
-16.3%
238.4M
+72.9%
137.9M
-40.4%
231.2M
EPS (Basic)
$1.01
-1.9%
$1.03
-15.6%
$1.22
+71.8%
$0.71
-39.3%
$1.17
EPS (Diluted)
$1.00
-2.9%
$1.03
-15.6%
$1.22
+74.3%
$0.70
-39.7%
$1.16
Shares (Diluted)
191.4M
-0.7%
192.8M
-1.5%
195.8M
-1.1%
198.0M
-0.4%
198.8M
Zimmer Biomet (ZBH) — Financials